Mycosis fungoides and Sézary syndrome comprise the majority of cutaneous T cell lymphomas (CTCLs), disorders notable for their clinical heterogeneity that can present in skin or peripheral blood. Effective treatment options for CTCL are limited, and the genetic basis of these T cell lymphomas remains incompletely characterized 1 . Here we report recurrent point mutations and genomic gains of TNFRSF1B, encoding the tumor necrosis factor receptor TNFR2, in 18% of patients with mycosis fungoides and Sézary syndrome. Expression of the recurrent TNFR2 Thr377Ile mutant in T cells leads to enhanced non-canonical NF-B signaling that is sensitive to the proteasome inhibitor bortezomib. Using an integrative genomic approach, we additionally discovered a recurrent CTLA4-CD28 fusion, as well as mutations in downstream signaling mediators of these receptors.
Mycosis fungoides and Sézary syndrome comprise the majority of cutaneous T cell lymphomas (CTCLs), disorders notable for their clinical heterogeneity that can present in skin or peripheral blood. Effective treatment options for CTCL are limited, and the genetic basis of these T cell lymphomas remains incompletely characterized 1 . Here we report recurrent point mutations and genomic gains of TNFRSF1B, encoding the tumor necrosis factor receptor TNFR2, in 18% of patients with mycosis fungoides and Sézary syndrome. Expression of the recurrent TNFR2 Thr377Ile mutant in T cells leads to enhanced non-canonical NF-B signaling that is sensitive to the proteasome inhibitor bortezomib. Using an integrative genomic approach, we additionally discovered a recurrent CTLA4-CD28 fusion, as well as mutations in downstream signaling mediators of these receptors.
We performed whole-exome sequencing on 11 mycosis fungoides and Sézary syndrome samples each paired with a normal sample to identify somatic genetic alterations associated with these malignancies (Supplementary Table 1 ). A total of 494 genes were selected for deep targeted resequencing, which included genes mutated in the exome data set, genes previously implicated in the pathogenesis of T cell malignancies and related pathway members (Supplementary  Tables 2-7) . A total of 91 individual samples and cell lines were sequenced at an average coverage of ~700×, of which 73 were included in our mycosis fungoides and Sézary syndrome paired analysis with normal samples (Supplementary Fig. 1 and Supplementary Table 8 ).
The mutational spectrum of mycosis fungoides and Sézary syndrome is heterogeneous, with the tumor-suppressor genes MLL3 (also known as KMT2C; 26%) and TP53 (13%) being the two most frequently mutated genes (Supplementary Fig. 2 ). Furthermore, we found gainof-function mutations in KRAS and PLCG1 that have previously been reported in mycosis fungoides and Sézary syndrome 2, 3 . The most frequent recurrent point mutation in our data set occurred at codon 377 of TNFRSF1B (5%; 4/73), encoding tumor necrosis factor receptor 2 (TNFR2), resulting in a recurrent TNFR2 Thr377Ile mutant. TNFR2 is a receptor that regulates key T cell signaling pathways and has not previously been implicated in cancer (Fig. 1a) 4 .
We noted that many somatic alterations involved pathways related to TNFR2 and non-canonical nuclear factor (NF)-κB signaling, primarily regulating T cell survival and proliferation (Fig. 1a) , including the TNFR2 pathway itself, as well as the T cell receptor (TCR) and CD28 pathways. This finding is consistent with previous transcriptome sequencing indicating differential expression of genes in the TCR signaling pathway between Sézary syndrome cells and autologous polyclonal CD4 + T cells 5 . In addition to alterations in TNFR2, we found mutations in phosphoinositide 3-kinase (PI3K)-related genes involved in TCR-CD28 signaling and mutations in NF-κB pathway genes, including a subset in the canonical NF-κB signaling pathway ( Supplementary Fig. 2b) , that control transcriptional programs downstream of key T cell signaling pathways (Fig. 1a,b) 4 .
Structural variations frequently characterize malignancies of lymphoid origin, and we therefore used FACTERA to detect chromosomal structural variations in mycosis fungoides and Sézary syndrome samples 6 . This analysis identified structural variation events (excluding copy number gains) in pathways related to T cell survival and proliferation in 11% of patients with mycosis fungoides or Sézary syndrome (Supplementary Table 9 ). Interestingly, the structural variants were largely mutually exclusive with the TNFR2 alterations (Fisher's exact test, P = 0.0005). The structural variants included NFKB2 gene truncations in 5% (4/73) of cases with the deletion of a region whose loss is known to generate a truncated p100 protein with predicted proteasome-independent NF-κB2 nuclear localization 7, 8 (Fig. 2a) , as well as a deletion involving TRAF3 that would also be expected to increase non-canonical NF-κB signaling (Fig. 2b) . We also identified a translocation altering the TP63 gene recently reported to be Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2 rearranged in T cell lymphomas ( Supplementary Fig. 3a,b) 9 , two translocations predicted to disrupt the CD274 gene, encoding PD-L1, which normally inhibits T cell activation via PD1 binding (Fig. 2c) 10 , and a translocation predicted to delete the pro-apoptotic TNFRSF10A receptor ( Supplementary Fig. 3c,d ) 11 .
We further detected in two patients a large deletion on chromosome 2 involving the functionally antagonistic surface receptors CTLA4 and CD28, fusing the extracellular portion of the inhibitory CTLA4 protein to the co-activating cytoplasmic tail of CD28 ( Fig. 2d and Supplementary Fig. 3e-g ). CTLA4 binds the shared ligands (B7-1 and B7-2) with higher affinity and avidity than CD28, and, on the basis of experiments in mouse T cells, an extracellular CTLA4 domain fused to the signaling domain of CD28 would be expected to transmit powerful co-stimulatory signals in T cells 12 . Consistent with this expectation, Jurkat cells engineered to express this fusion construct proliferated faster than cells with empty vector or those overexpressing CTLA4 ( Fig. 2e and Supplementary Fig. 3h) . Consequently, the CTLA4-CD28 fusion may be an oncogenic driver in a subset of patients with mycosis fungoides and Sézary syndrome that leads to enhanced lymphoma cell proliferation in a normally inhibitory cellular milieu. This fusion may represent a therapeutic opportunity in this subset of patients for use of the CTLA4-blocking antibody ipilimumab 13 , a possibility supported by a recent study of a single case 14 .
TNFR2 expression is restricted to a few cell types, including mature T cells, where it enhances T cell activation and survival via non-canonical NF-κB signaling 15 . Interestingly, patients with mycosis fungoides or Sézary syndrome frequently also have genomic gains of a 1.25-Mb region of chromosome 1p36.2 that includes the TNFRSF1B (TNFR2) locus 16 , and in peripheral T cell lymphomas higher levels of soluble TNFR2 are prognostic for poor outcome 17 . We used digital droplet PCR (ddPCR) to confirm that the TNFRSF1B (TNFR2) locus was subject to somatically acquired copy number gain in 14% (10/73) of patients with mycosis fungoides and Sézary syndrome in our cohort and also demonstrated this gain in one additional patient by FISH analysis (Figs. 1b and 3a,b, and Supplementary Fig. 4a ). This gain correlated with increased TNFRSF1B transcript levels in patient tumor samples and with increased TNFR2 protein levels in the HH CTCL cell line that harbors this gain 18 (Fig. 3c-e and Supplementary Fig. 4b ).
In total, TNFRSF1B was altered in 18% (13/73) of patients with mycosis fungoides and Sézary syndrome by either point mutation or gain, suggesting a potential role of oncogenic TNFR2 signaling in the development of these diseases.
In the context of a heterogeneous mutation landscape, 38% (28/73) of the patients sequenced demonstrated a genetic abnormality in TNFR2-related T cell signaling pathways. TNFRSF1B lesions were the only alterations that were statistically enriched in Sézary syndrome in comparison to mycosis fungoides (P = 0.0043; Supplementary Table 10 ). The distribution of TNFRSF1B lesions was significantly enriched in stage IV disease (P = 0.0073). Moreover, patients with mycosis fungoides and lesions in the TNFR2-related pathway were significantly enriched for large-cell transformation (LCT; P = 0.007), which correlated with a higher overall mutation rate and poorer survival in our cohort ( Supplementary Fig. 5a,b) . Multivariate analysis suggested that, although TNFR2 pathway mutations are statistically correlated with worse survival, these findings are confounded by stage and LCT status, which are independent predictors of survival ( Supplementary Fig. 5b-d and Supplementary Table 11 ). Of note, several other parameters examined did not correlate with differences in patient survival, including number of mutations, age, diagnosis or other mutation combinations ( Supplementary Fig. 5e-i) .
Analysis of previous Sézary syndrome transcriptome data 5 identified increased TNFRSF1B transcript levels in Sézary syndrome in all three patients analyzed in comparison with autologous polyclonal CD4 + T cells (Fig. 3f) . Using gene set enrichment analysis (GSEA), we identified the TNF pathway as the highest-scoring TNFR2-dependent expression signature in 24 patients with mycosis fungoides (Fig. 4a) . This result suggested that alterations in TNFR2 levels in this context meaningfully alter TNF pathway signaling to affect gene expression in this lymphoma.
The observed recurrent TNFRSF1B c.1130C>T mutation resulting in p.Thr377Ile involves a highly conserved threonine residue in the TRAF2 regulatory domain of TNFR2 (Fig. 4b,c) 19 . To test the potential functional impact of this substitution, we introduced either the wild-type or mutant receptor at physiological expression levels into Jurkat cells that do not express endogenous TNFR2 and assessed noncanonical NF-κB pathway activation ( Supplementary Fig. 6a,b) . Specifically, we analyzed TRAF2 levels and processing of p100 to p52 l e t t e r s npg l e t t e r s by immunoblotting. We found that TNFR2 Thr377Ile expression led to increased TRAF2 degradation and proteolytic processing of p100 to p52 in comparison to expression of wild-type TNFR2 (Fig. 4d-f) .
In a subcutaneous tumor model in mice, tumors expressing wild-type TNFR2 or TNFR2 Thr377Ile grew to larger size than tumors with an empty vector control (Supplementary Fig. 7a ). npg l e t t e r s
As expected, the Jurkat cells expressing wild-type TNFR2 and TNFR2 Thr377Ile underwent alterations in gene expression that involved the TNFR2 signature identified in patients with mycosis fungoides (Fig. 4g,h) . Consistent with the enhanced proteolytic processing of the NFKB2 gene product p100, we determined that the amplitude of NF-κB target gene expression was significantly increased by expression of TNFR2 Thr377Ile in comparison to wild-type TNFR2 (Fig. 4i) . Previous studies showing increased NF-κB activity in patients with CTCL motivated early-phase clinical studies of the proteasome inhibitor bortezomib in this disease 20 . On the basis of the observed therapeutic benefit in a subset of patients, we treated Jurkat cells expressing wild-type or mutant TNFR2 with bortezomib, leading to a reversal in the expression of a subset of the TNFR2-responsive genes that were statistically enriched for leukocyte activation, signaling and apoptosis (Fig. 4j) . Interestingly, the Jurkat cells expressing wild-type TNFR2 or TNFR2 Thr377Ile were more responsive to bortezomib than control cells with empty vector, suggesting that TNFR2 pathway activation is specifically targeted by this proteasome inhibitor (Supplementary Fig. 7b ). To further test this hypothesis, we used HH cells, a CTCL cell line that contains a TNFRSF1B (TNFR2) genomic gain 18 , and CRISPR-Cas9 technology to generate an HH TNFR2-knockout line (Supplementary Fig. 7c ). As predicted, the TNFR2-knockout HH cells were less sensitive to bortezomib treatment, despite no significant differences in cell viability under normal growth conditions ( Supplementary Fig. 7d,e) . Additionally, we compared HH cells to Hut78 cells that contain an NFKB2 gene truncation 8 ; as expected, the Hut78 cells were less sensitive to the proteasome inhibitor than HH cells (Supplementary Fig. 7f ). These data provide a mechanistic rationale for the activity of bortezomib observed in a subpopulation of patients with mycosis fungoides and Sézary syndrome and warrant npg further testing of TNFR2 pathway alterations as a predictive biomarker for the efficacy of proteasome inhibitor therapy in this disease. In this study, we identify recurrent alterations in the TNFR2 pathway in addition to other genes regulating T cell survival and proliferation that affect more than a third of patients with mycosis fungoides and Sézary syndrome. Of these patients, over half may benefit from either approved medications or drugs currently in clinical development targeting PI3K isoforms, CTLA4 and NF-κB processing. Future studies are needed to investigate the efficacy of targeted agents in patients with mycosis fungoides and Sézary syndrome prospectively selected on the basis of their genomic profiles.
METHodS
Methods and any associated references are available in the online version of the paper. 
oNLINE METHodS
Cutaneous T cell lymphoma samples. CTCL and matched normal control samples were collected with informed consent prospectively under a protocol approved by the Institutional Review Board at Stanford University Medical Center (IRB21750). Skin biopsies were stored in RNAlater (Ambion), and peripheral blood samples were processed by Ficoll gradient centrifugation, magnetic bead-mediated CD4 selection (Miltenyi) or flow cytometry to separate lymphoma cells from other peripheral blood leukocytes. Primarily skin biopsies were used for patients with a mycosis fungoides diagnosis and sorted or enriched lymphoma cells were used for patients with Sézary syndrome, although there were a few exceptions (Supplementary Table 9 ). All patient characteristics used for genomic analysis are from the time of biopsy, except for the patient's original diagnosis of either mycosis fungoides or Sézary syndrome.
Cell culture. Jurkat cells, HH cells and Hut78 cells were obtained from the American Type Culture Collection (ATCC); MyLa and SeAx cells were a generous gift from K. Kalthoft (Aarhus University). Cells were grown in RPMI-1640 medium (Life Technologies) supplemented with 10% BCS (Jurkat, HH and MyLa cells), IMDM supplemented with 20% BCS (Life Technologies) (Hut78 cells) or primary T cell medium (SeAx cells; RPMI-1640 medium supplemented with 14 µM β-mercaptoethanol, 10% BCS, 5% human AB serum (Sigma), 200 IU/ml interleukin (IL)-2, 20 ng/ml IL-7 and 20 ng/ml IL-15 (Peprotech)). All cells were grown at 37 °C in a humidified chamber with 5% CO 2 and were routinely tested for mycoplasma contamination.
Library preparation and sequencing. Exome sequencing libraries were prepared using the TruSeq DNA Library Prep kit, and enrichment was performed with EZexome V2.0 Early Access for Capture by Ambry Genetics. Genes for targeted resequencing were chosen on the basis of mutation in the original whole-exome sequencing data together with additional targets related to genes that were mutated and genes previously reported to be mutated in T cell lymphomas. Targeted resequencing libraries were prepared using the Illumina TruSeq kit (starting with 1 µg of genomic DNA) with barcodes. Libraries were pooled, and capture was performed with two distinct capture reagents targeting 1.2-Mb and 3.1-Mb regions of interest (SeqCap EZ, NimbleGen, Roche). The SeqCap EZ custom capture reagent is a solution-based capture protocol that uses specific regions of interest from pre-prepared libraries to enable targeted capture followed by resequencing. Before library preparation, certain DNA samples without sufficient amounts of starting material underwent whole-genome amplification (GenomePlex, Sigma). The libraries were sequenced with the Illumina HiSeq platform using 101-bp paired-end sequencing. RNA sequencing libraries were generated with the Illumina RNA TruSeq kit. Libraries were barcoded, pooled and sequenced with the Illumina HiSeq platform using 101-bp paired-end sequencing. SNP arrays. SNP array analysis was performed on the HH, Hut78, MyLa and SeAx cell lines as well as Sézary syndrome 15 DNA using the Affymetrix SNP 6.0 chip. SNP calls were made using the Affymetrix Genotyping Console 4.0. Using the set of SNPs that were identified as differing from the hg19 reference genome for all of the SNP arrays that also fell into the resequencing capture regions, sensitivity was calculated as the fraction of these SNPs that were identified as differing from the reference and specificity was calculated as the fraction of these SNPs that were identified to have the same genotype.
Single-nucleotide variant and fusion analysis. Paired-end alignment was performed with Burrows-Wheeler Aligner (BWA) 22 to the hg19 reference using default parameters. Single-nucleotide variant (SNV) calling was performed by the Genome Analysis Toolkit (GATK) 23 , VarScan 24 and SeqGene 25 . GATK was run by following the Best Practices v3 guidelines for exomes, using Indel Realignment, the Unified Genotyper, the Variant Quality Score Recalibrator and Variant Filtration as recommended 23 . Quality scores of ≥50 were required for a call, whereas a quality score of ≥10 was accepted for emitting. Recalibration was performed to the 1000 Genomes Project and HapMap 3.3 SNPs provided in the resource bundle. Resequencing analysis was recalibrated to the Mills and 1000 Genomes Gold Standard package with a maximum Gaussians parameter of 4. Variants were further filtered for clusters of greater than three SNVs in a 10-bp window. VarScan was run with default parameters. SeqGene was run with a threshold of 0.1 for SNV calling, and all other parameters were default. No minimum threshold was set for the resequencing analysis. Exome sequencing downstream analysis of GATK-called SNVs was performed on calls in a tranche of 99.0 or better. VarScan and SeqGene results were further filtered for false positives by removing any calls not supported by at least one read in each direction in the exome sequencing analysis. Unequal forward and reverse read distributions (beyond an 80%/20% split) were also removed from analysis. Low-coverage calls (<6 reads) were not held to this standard, but rather variant calls had to comprise at least 20% of the reads at that position. Resequencing was performed in two batches. Resequencing downstream analysis was performed on all acquired mutation calls on the basis of the genotype designated by the SNV caller. It was further required that the CTCL samples contain ≥2-fold enrichment of reads supporting the mutation in comparison to the control samples. For cell lines and patients with CTCL without a matched normal control sample, a minimum variant allele frequency of 0.1 was required. Annotations for all mutation calls were performed with SeattleSeq 26 . For patient samples that underwent whole-genome amplification, we found that amplification introduced many mutations. To avoid studying false positive mutations, all mutations that involved samples undergoing whole-genome amplification were excluded from analysis, figures and tables (but are included as a reference in dbGaP). Patient samples that did not have matched control samples were also not considered in further analyses but are included in the supplementary tables. Fusion analysis was performed with FACTERA using default parameters on aligned BAM files from resequencing. Fusion validation was performed using genomic PCR; the resulting products were gel purified from a 1% agarose gel and sequenced by Sanger sequencing (Elim Biopharmaceuticals). Statistics to evaluate the enrichment of TNFRSF1B mutations in stage IV disease were calculated using Fisher's exact test.
Selection of patients for various analyses. Our core analysis was based on the 73 patients with matched pairs, including the sample from patient mycosis fungoides 46 that underwent whole-genome amplification but whose TNFR2 p.Thr377Ile alteration was confirmed in the DNA before the amplification step. A total of 41 patients with mycosis fungoides and 32 patients with Sézary syndrome were analyzed in this study. All other mutations from mycosis fungoides 46 that were not validated by Sanger sequencing were excluded to avoid presenting false positive mutations. The characteristics for the 73 patients are described in Supplementary Table 9 . Of note, only 61 of the 73 patients contained mutations in our panel of resequencing genes; the mutations for these 61 patients are included in Supplementary Table 2. The 14 patients without matched control samples and those that underwent whole-genome amplification, as well as 4 CTCL cell lines (HH, Hut78, MyLa and SeAx cells), were not considered in further analyses as mutations could not be determined to be somatically acquired. We also sequenced the Jurkat cell line (a T cell leukemia line) and H9 cells (a subclone of Hut78 cells) that were not counted in our total of 91 samples as they are not unique CTCL samples. We included the mutations (from unmatched patient samples and cell lines) and source sequencing files on dbGaP (for unmatched patient samples, cell lines and whole genome-amplified samples) that were not considered in our analysis denominators to allow future researchers the opportunity to check for specific mutation(s) of interest.
Digital droplet PCR.
Genomic gains of TNFRSF1B were identified using ddPCR. ddPCR experiments were performed according to the manufacturer's guidelines (Digital Droplet PCR Application Guide, Bulletin 6407 Rev A) on a Bio-Rad QX100 system. Briefly, 50-200 ng of genomic DNA was digested with HindIII at 37 °C for 1 h. ddPCR assays were performed using 20 ng of digested genomic DNA, ddPCR supermix (Bio-Rad, 290-10420) and TaqMan probes against TNFRSF1B (FAM dye-labeled test probe) and RPP30 (VIC dye-labeled diploid reference probe; ABI, 4403326). We subjected 20-µl reactions to the following cycling program: 10 min at 95 °C, 40 cycles of 30 s at 95 °C and 1 min at 60 °C, and 10 min at 98 °C. Sample quantification was performed using QuantaSoft version 1.3.2. A cohort of 89 primary tumors and cell lines was initially screened in duplicate for copy number gains at the TNFRSF1B locus. Sample Sézary syndrome 120 was the only sample that was too dilute to interpret the results. Samples exceeding a TNFRSF1B gene ratio of 2.15 in tumor versus normal cells, which corresponds to 15% of the cell population exhibiting a 3N state, were reanalyzed with triplicate measurements and compared to measurements on paired normal samples where possible. Statistical npg
